Regarding this, circulating levels of this cytokine might be a useful biomarker to distinguish NASH from NAFL, and anti-TGF-β therapy could be a promising approach to alleviate liver fibrosis. This evidence concerns the gene TGFB1 and non-alcoholic fatty liver.